NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 420
(Total Views: 168)
Posted On: 06/16/2023 5:10:15 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Promising Results from Diabetes Animal Study
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is releasing additional findings from its DIAB-A22-1 study, a diabetes animal study designed to evaluate the company’s proprietary DehydraTECH-CBD. DehydraTECH is a patented drug-delivery formulation and processing platform technology developed by Lexaria. The company noted that in addition to the three positive outcomes reported earlier — weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels — the study has indicated a reduction in blood glucose levels and improvements in kidney function. These results were gathered after the company undertook a further round of analysis to explore additional study outcomes; the additional analysis included using an alternate blood glucose assay detection system with higher detection sensitivity. The company also reported updates on two of its applied R&D programs
EM-A22-1 and EPIL-A21-1. Lexaria’s DEM-A22-1 is a study designed to investigate whether DehydraTECH-CBD enables any procognitive performance enhancements with potential use in dementia treatment.
The company noted that the findings from this study were “generally unremarkable and several unexpected study complications may have muted efficacy distinction ability.” The EPIL-A21-1 was designed to evaluate the effectiveness of LEXX’s DehydraTECH-CBD compared to one of the world’s leading anti-seizure medications, Epidiolex(R), in reducing seizure activity. Initial findings from the study seemed to demonstrate that DehydraTECH-CBD had effectiveness at lower doses and with greater rapidity than Epidiolex. In the past few months, Lexaria has also completed a final study under its EPIL-A21-1 program that looked at establishing dosage amounts. “This ED50 study was designed with an objective to hopefully corroborate Lexaria’s prior MES experimental findings,” the company states in the press release. “Lexaria is pleased to confirm that the outcome demonstrated that DehydraTECH-CBD was most effective at a dose of 75 mg/Kg, also as previously reported from the initial round of work in this animal model, which compared favorably to Epidiolex that generally required a higher dose of 100 mg/Kg to achieve comparable findings.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is releasing additional findings from its DIAB-A22-1 study, a diabetes animal study designed to evaluate the company’s proprietary DehydraTECH-CBD. DehydraTECH is a patented drug-delivery formulation and processing platform technology developed by Lexaria. The company noted that in addition to the three positive outcomes reported earlier — weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels — the study has indicated a reduction in blood glucose levels and improvements in kidney function. These results were gathered after the company undertook a further round of analysis to explore additional study outcomes; the additional analysis included using an alternate blood glucose assay detection system with higher detection sensitivity. The company also reported updates on two of its applied R&D programs
EM-A22-1 and EPIL-A21-1. Lexaria’s DEM-A22-1 is a study designed to investigate whether DehydraTECH-CBD enables any procognitive performance enhancements with potential use in dementia treatment. The company noted that the findings from this study were “generally unremarkable and several unexpected study complications may have muted efficacy distinction ability.” The EPIL-A21-1 was designed to evaluate the effectiveness of LEXX’s DehydraTECH-CBD compared to one of the world’s leading anti-seizure medications, Epidiolex(R), in reducing seizure activity. Initial findings from the study seemed to demonstrate that DehydraTECH-CBD had effectiveness at lower doses and with greater rapidity than Epidiolex. In the past few months, Lexaria has also completed a final study under its EPIL-A21-1 program that looked at establishing dosage amounts. “This ED50 study was designed with an objective to hopefully corroborate Lexaria’s prior MES experimental findings,” the company states in the press release. “Lexaria is pleased to confirm that the outcome demonstrated that DehydraTECH-CBD was most effective at a dose of 75 mg/Kg, also as previously reported from the initial round of work in this animal model, which compared favorably to Epidiolex that generally required a higher dose of 100 mg/Kg to achieve comparable findings.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼